Hannah C. Jeffery, Manjit K. Braitch, Chris Bagnall, James Hodson, Louisa E. Jeffery, Rebecca E. Wawman, Lin Lee Wong, Jane Birtwistle, Helen Bartlett, Ansgar W. Lohse, Gideon M. Hirschfield, Jessica Dyson, David Jones, Stefan G. Hubscher, Paul Klenerman, David H. Adams, Ye H. Oo – 26 February 2018 – Autoimmune hepatitis (AIH) is an immune‐mediated liver disease currently treated by immunosuppressive medications with significant side effects. Thus, novel mechanistic treatments are greatly needed.

26 February 2018

Russell Rosenblatt, Robert S. Brown, Saurabh Mukewar, Yecheskel Schneider, Robert E. Schwartz, Shirley Cohen‐Mekelburg, Clara Tow, Aleksey Novikov, Nicholas Russo, Zaid H. Tafesh, Vikas Gupta – 26 February 2018

26 February 2018

26 February 2018

Russell Rosenblatt, Robert S. Brown, Saurabh Mukewar, Yecheskel Schneider, Robert E. Schwartz, Shirley Cohen‐Mekelburg, Clara Tow, Aleksey Novikov, Nicholas Russo, Zaid H. Tafesh, Vikas Gupta – 26 February 2018

Yao‐Yao Zhou, Xiao‐Dong Zhou, Sheng‐Jie Wu, Dan‐Hong Fan, Sven Poucke, Yong‐Ping Chen, Shen‐Wen Fu, Ming‐Hua Zheng – 26 February 2018 – Nonalcoholic fatty liver disease (NAFLD) is associated with an increased risk of atherosclerotic cardiovascular disease. In our meta‐analysis, we aimed to assess the correlation of NAFLD and four surrogate markers of subclinical atherosclerosis. PubMed, Embase, and the Cochrane Library were searched up until April 2017. Original studies investigating the association between NAFLD and subclinical atherosclerosis were included.

Teresa Maria Antonini, Olivier Guillaud, Jérôme Dumortier, Sébastien Dharancy, Faouzi Saliba, Philippe Mathurin, Jean‐Charles Duclos‐Vallée, Christophe Duvoux, for Groupe de Recherche Français en Greffe de Foie (GReF2) – 24 February 2018

Astrid Ruiz‐Margáin, Alessandra Pohlmann, Patrick Ryan, Robert Schierwagen, Luis A. Chi‐Cervera, Christian Jansen, Osvely Mendez‐Guerrero, Nayelli C. Flores‐García, Jennifer Lehmann, Aldo Torre, Ricardo Ulises Macías‐Rodríguez, Jonel Trebicka – 24 February 2018 – Acute‐on‐chronic liver failure (ACLF) develops in acute decompensation (AD) of cirrhosis and shows high mortality. In critically ill patients, early diagnosis of ACLF could be important for therapeutic decisions (eg, renal replacement, artificial liver support, liver transplantation).

Annsa C. Huang, Neil Mehta, Jennifer L. Dodge, Francis Y. Yao, Norah A. Terrault – 24 February 2018 – Whether direct‐acting antivirals (DAAs) increase the risk of hepatocellular carcinoma (HCC) recurrence after tumor‐directed therapy is controversial. We sought to determine the impact of DAA therapy on HCC recurrence after local‐regional therapy (LRT) and waitlist dropout among liver transplant (LT) candidates with HCC. We performed a retrospective cohort study of 149 LT candidates with hepatitis C virus (HCV) and HCC at a single center from 2014 through 2016.